Loading patent…
AssigneeHitgen Inc.
InventorsRuizhi Guo, Jiansong Wang, Zhibo Luo, Haiwen Huang, Fei Qin, Wei Wang, Haihong Ye, Ribin Qian
Estimating the term…
The present invention relates to the technical field of drug synthesis. Disclosed are a crystal form of a macrocyclic compound, and a preparation method therefor and the use thereof. The macrocyclic compound is (6R,16R)-9-fluoro-16-methyl-13-oxa-2,17,21,25-tetraazapentane [16.6.2.02,6.07,12.022,26]dihexadecane-1(25),7,9,11,18(26),19,21,23-octane-19-carbonitrile. The X-ray diffraction pattern of the crystal form has characteristic peaks at 2θ values of 9.49±0.2, 10.60±0.2, 11.54±0.2, 14.10±0.2, 17.09±0.2, 19.15±0.2, 20.30±0.2, 22.85±0.2, 23.89±0.2 and 27.74±0.2. The crystal form is hygroscopicity-free, has a good stability and pharmacokinetic properties.
A crystal form of a macrocyclic compound (6R,16R)-9-fluoro-16-methyl-13-oxa-2,17,21,25-tetraazapentacyclo [16.6.2.02,6.07,12.022,26] hexacosane-1(25),7,9,11,18(26), 19,21,23-octane-19-carbonitrile, wherein the X-ray powder diffraction pattern of the crystal form comprises characteristic peaks at 2θ values of 9.49±0.2, 10.60±0.2, 11.54±0.2, 14.10±0.2, 17.09±0.2, 19.15±0.2, 20.30±0.2, 22.85±0.2, 23.89±0.2 and 27.74±0.2.
Dependencies are inferred from the claim text.